103733-31-9 Usage
Uses
Used in Pharmaceutical Industry:
(S)-6,7-DIMETHOXY-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINE CARBOXYLIC TERT BUTYL ESTER is used as an intermediate in the synthesis of Moexipril (M485350), a medication used for treating hypertension and heart failure. Its role in the pharmaceutical industry is crucial for the preparation of this drug and its impurities, ensuring the development of effective and safe medications for patients.
Used in Chemical Research:
As a complex organic compound, (S)-6,7-DIMETHOXY-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINE CARBOXYLIC TERT BUTYL ESTER can also be used in chemical research for studying the properties and reactivity of tetrahydroisoquinoline derivatives. This can lead to the discovery of new compounds with potential applications in various fields, such as pharmaceuticals, materials science, and agrochemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 103733-31-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,7,3 and 3 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 103733-31:
(8*1)+(7*0)+(6*3)+(5*7)+(4*3)+(3*3)+(2*3)+(1*1)=89
89 % 10 = 9
So 103733-31-9 is a valid CAS Registry Number.
InChI:InChI=1/C16H23NO4/c1-16(2,3)21-15(18)12-6-10-7-13(19-4)14(20-5)8-11(10)9-17-12/h7-8,12,17H,6,9H2,1-5H3/t12-/m0/s1
103733-31-9Relevant academic research and scientific papers
Breen, Christopher P.,Jamison, Timothy F.
, p. 14527 - 14531 (2019)
A strategy for the continuous flow synthesis of angiotensin converting enzyme (ACE) inhibitors is described. An optimization effort guided by in situ IR analysis resulted in a general amide coupling approach facilitated by N-carboxyanhydride (NCA) activation that was further characterized by reaction kinetics analysis in batch. The three-step continuous process was demonstrated by synthesizing 8 different ACE inhibitors in up to 88 % yield with throughputs in the range of ≈0.5 g h?1, all while avoiding both isolation of reactive intermediates and process intensive reaction conditions. The process was further developed by preparing enalapril, a World Health Organization (WHO) essential medicine, in an industrially relevant flow platform that scaled throughput to ≈1 g h?1.
